Dynavax Technologies reported $37.92M in Gross Profit on Sales for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
TG Therapeutics TGTX:US 1.74M 341K
Adma Biologics ADMA:US $ 0.38M 1.39M
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Amgen AMGN:US $ 5097M 208M
AstraZeneca AZN:LN 6.04B 15M
Astrazeneca AZN:US 6.04B 15M
Biogen BIIB:US $ 2267.1M 48.2M
Biomarin Pharmaceutical BMRN:US $ 305.2M 69.43M
Bristol Myers Squibb BMY:US $ 9333M 81M
Gilead Sciences GILD:US $ 6198M 1371M
Glaxosmithkline GSK:US $ 6255M 682M
Gw Pharmaceuticals GWPH:US $ 140.66M 2.86M
Merk MRK:US $ 10098M 1738M
Nektar Therapeutics NKTR:US $ 19.61M 1.05M
Neurocrine Biosciences NBIX:US $ 291.8M 6M
Novartis NOVN:VX 9.52B 21M
Pfizer PFE:US $ 14163M 2178M
Regeneron Pharmaceuticals REGN:US $ 2999.6M 1445.2M
Sarepta Therapeutics SRPT:US $ 165.96M 21.39M
Vertex Pharmaceuticals VRTX:US $ 1747.65M 182.25M